German Biochemist Questions Efficacy of Alzheimer's Antibody Therapies

A German biochemist, Christian Behl, expresses skepticism regarding the effectiveness of new antibody therapies for Alzheimer's disease, advocating for alternative research approaches and highlighting factors that increase dementia risk.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

fazGerman71d ago

Behandlung von Demenz: „Antikörper sind nicht der Gamechanger bei Alzheimer“

Im Kampf gegen Alzheimer ruht die Hoffnung auf neuen Antikörper-Therapien. Der Mainzer Biochemiker Christian Behl zweifelt deren Nutzen an. Er fordert neue Forschungsansätze und sagt, was das Risiko für Demenz erhöht.

Read full article →

German Biochemist Questions Efficacy of Alzheimer's Antibody Therapies

Sources

Behandlung von Demenz: „Antikörper sind nicht der Gamechanger bei Alzheimer“

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Novartis Pauses Autoimmune Cell Therapy Trials After Patient Deaths

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases